Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, and internationally. The company operates in two segments, Commercial and Research. It offers Cxbladder, a genomic urine tests for the detection and management of bladder cancer. The company is also developing Cxbladder Triage, a product that identifies patients with haematuria who have a low probability of bladder cancer; Cxbladder Detect that enables the non-invasive detection of bladder and other urinary tract cancers; and Cxbladder Monitor, which allows urologists to monitor bladder cancer patients for recurrence of the disease. In addition, it is developing products for bladder, gastric, colorectal, endometrial cancers, and melanoma. The company was incorporated in 2001 and is headquartered in Dunedin, New Zealand.